Kenvue (NYSE:KVUE) PT Raised to $21.00

Kenvue (NYSE:KVUE) had its target price increased by research analysts at HSBC from $20.00 to $21.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. HSBC’s target price indicates a potential upside of 2.24% from the company’s current price.

Several other research firms have also commented on KVUE. JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Sanford C. Bernstein started coverage on Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. Royal Bank of Canada lowered their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. William Blair began coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus price target of $24.38.

Kenvue Price Performance

KVUE opened at $20.54 on Wednesday. Kenvue has a twelve month low of $17.82 and a twelve month high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The firm’s 50-day moving average price is $19.90 and its 200 day moving average price is $20.12.

Kenvue (NYSE:KVUE) last issued its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $3.79 billion. The firm’s quarterly revenue was down 24.9% on a year-over-year basis. As a group, equities analysts expect that Kenvue will post 1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KVUE. Clearstead Advisors LLC purchased a new stake in shares of Kenvue in the 3rd quarter valued at approximately $25,000. Manchester Capital Management LLC increased its holdings in Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after buying an additional 530 shares during the last quarter. Planned Solutions Inc. acquired a new position in shares of Kenvue in the 4th quarter valued at $27,000. Venturi Wealth Management LLC purchased a new position in shares of Kenvue in the 3rd quarter valued at $28,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in Kenvue during the 3rd quarter worth $28,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.